logo
What's Right With Schools: Bristol students raise money to help Man with ALS get new service dog

What's Right With Schools: Bristol students raise money to help Man with ALS get new service dog

Yahoo03-06-2025
BRISTOL, Conn. (WTNH) — A classroom is coming together to make a difference in someone's life. They're getting creative and raising money for a cause.
Step into the hallway of St. Matthew School in Bristol. Students are on a mission, pushing a cart full of items they've made.
What's Right with Schools: Students in Columbia learn about future career opportunities
'My friends and I we made bracelets…And we crocheted some headbands and cute little animals and we just made some slime and liked selling it to the kids,' Fifth grader Emily Mullins said.
It's a real business they came up with.
Meet Swanson, the loyal service dog who dedicated his life to Stuart Sherman, who lives with ALS.
'He was diagnosed with ALS 12 years ago. And honestly, I thought he wouldn't be here. As the diagnosis said, 3-5 years, we'd lose him,' Celeste Valenti Sherman, Stuart's wife, said.
She credits prayer and perhaps this partner with paws, who has him outliving that dark diagnosis.
'I take care of her… She takes care of me,' Sherman said.
He was once self-conscious about going out in public with his physical changes, but the dog first gave him confidence.
'He hand cycles marathons, he goes to the gym every day. He's done what, 7 marathons, he's training for a half in June,' she said. 'I always say he's in love with another woman, and I don't care, that's fine.'
But sadly, Swanson is tired. Now they need to raise money for another service animal so she can retire.
To give you some perspective, service dogs like this typically retire at the age of 10 or 11, because of a shortage. Swanson is 12, so it's time for her to live out her golden years.
That's where Jessica Martineau's fifth-grade class comes in. They met the pair and wanted to help.
'They wanted to help Swanson retire and still have Stuart have another puppy,' Jessica Martineau, a fifth-grade teacher, said. 'On rainy days, cold days, instead of choosing Legos or free draw. These kids were making bracelets, crocheting animals for the store.'
'I made some slime like I would help with the prices and all the other stuff,' Michael Marino said.
The goal was $500, and the result was double that.
'We would like to give Stuart and Celeste a check of $1,000 from the fifth-grade class,' Martineau said.
Hard work, crafting, and selling. A gift from the heart to a lovable pair.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

Business Wire

timean hour ago

  • Business Wire

Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ('Apimeds' or the 'Company'), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company's proprietary ai²™ division. Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division Dr. Kramer brings more than 30 years of experience in biopharmaceutical research and development, including 18 years at Genentech. She most recently served as Executive Vice President of Development at Concentric Analgesics. Mr. Peters, previously Chief Strategy & Insights Officer at Heller Agency, has a proven track record in healthcare innovation, strategic communications, and KOL engagement. In their new roles, Dr. Kramer will oversee all product development activities at Apimeds, while Mr. Peters will lead the strategy, positioning, and launch of the Company's ai²™ platform. 'We're thrilled to welcome Susan and Brian to the Apimeds leadership team,' said Erik Emerson, Chief Executive Officer of Apimeds. 'Strengthening our operational leadership has been a priority since our IPO. Susan enhances our clinical development capabilities at a pivotal time for Apitox, while Brian brings vision, energy, and deep strategic expertise as we build and scale our ai²™ platform.' ' Apitox is an incredibly exciting program,' said Dr. Kramer. 'Having worked with Erik in the past, I know the caliber of his leadership. The scientific potential of purified bee venom and the company's mission made this an easy decision. I'm eager to explore the range of indications where Apitox may bring meaningful therapeutic benefits.' 'Joining Apimeds at this inflection point is an amazing opportunity,' added Mr. Peters. 'The chance to shape and launch ai²™—our internal innovation engine—is compelling in its own right, but combining it with a pipeline as novel as Apitox makes this a truly unique moment.' Dr. Kramer is a co-founder of Corthera, Inc. (acquired by Novartis), and has held senior roles at XOMA, Anesiva, and Annexon Biosciences. She has led global development teams for both biologics and small molecules. She holds a BA from the College of St. Scholastica, an MA in Education from Central Michigan University, and both an MPH and DrPH in Biomedical Sciences (Virology) from the University of California, Berkeley. She has served on numerous boards and scientific advisory committees. Mr. Peters previously served as VP of Sales & Marketing and as a member of the corporate leadership team at Medexus Pharma from 2013 to 2024. Earlier in his career, he held senior leadership positions at Gilead Sciences, Accera, Chiesi, and G.D. Searle. He earned a BA in Communications from Indiana University. About Apimeds Pharmaceuticals US, Inc. Apimeds is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered honeybee venom-based toxin. Apimeds is currently developing Apitox as a potential treatment for osteoarthritis knee pain in patients who fail to respond adequately to conservative non-pharmacologic therapy and common analgesics. For more information, please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated use of the net proceeds from the offering. No assurance can be given that the net proceeds of the Offering will be used as indicated. All statements other than statements of historical facts are forward-looking statements. You can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'likely to' or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy and financial needs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include forward-looking statements include, but are not limited to, the risks and uncertainties described in 'Special Note Regarding Forward-Looking Statements,' 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and the documents that referred to in the prospectus filed with the SEC with the understanding that the Company's future results may be materially different from and worse than what we expect. Copies are available on the SEC's website, Other sections of the prospectus include additional factors which could adversely impact the Company's business and financial performance. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for the Company's management to predict all risk factors and uncertainties, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company and the underwriters qualify all of the forward-looking statements by these cautionary statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the prospectus relate only to events or information as of the date on which the statements are made in the prospectus. Neither the Company nor the underwriters undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read the prospectus and the documents that we refer to in the prospectus and have filed as exhibits to the registration statement, of which the prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.

Hims & Hers Health, Inc. (HIMS) Announces Expansion To Canada
Hims & Hers Health, Inc. (HIMS) Announces Expansion To Canada

Yahoo

timean hour ago

  • Yahoo

Hims & Hers Health, Inc. (HIMS) Announces Expansion To Canada

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and wellness platform announced plans to expand in Canada by offering generic semaglutide. A nurse in a telehealth platform talking with a patient on video call for consultation. This comes at a time when Novo Nordisk is set to lose its patent protection on Ozempic and Wegovy in Canada for not paying a maintenance fee in 2019. Hims & Hers Health, Inc. (NYSE:HIMS) joins a growing list of companies that are capitalizing on Novo Nordisk's lapsed patent on its GLP-1s. The introduction of generics is a pivotal moment for Canada's healthcare industry. With about two-thirds of adults in the country being overweight or obese, access to treatments has remained elusive for many due to the high costs. Hims & Hers Health, Inc. (NYSE:HIMS) intends to offer generic semaglutide at a significant discount to the currently branded versions, with prices expected to further decrease over time. Hims & Hers Health, Inc. (NYSE:HIMS)'s decision to enter the Canadian market follows the company's acquisition of European telehealth platform, Zava, in June, which will expand its services to France, Germany, and Ireland, and grow its active customer base by approximately 50%. While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best German Stocks to Invest in Now and Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Right-to-Die Activist Ends Life by Starving Herself to ‘Protect My Children From Seeing Me Choke and Struggle to Breathe'
Right-to-Die Activist Ends Life by Starving Herself to ‘Protect My Children From Seeing Me Choke and Struggle to Breathe'

Yahoo

time2 hours ago

  • Yahoo

Right-to-Die Activist Ends Life by Starving Herself to ‘Protect My Children From Seeing Me Choke and Struggle to Breathe'

Two years ago, Emma Bray, 42, was diagnosed with a terminal neurological condition called motor neuron disease She decided to end her life by starving herself, hoping to spare her children from witnessing her decline any further The mom of two announced her own death on Instagram on July 14 alongside a final photo of herself lying in a hospice bedA British mother made the tough decision to starve herself to death to spare her children from witnessing the devastating effects of her terminal neurological condition. Two years ago, Emma Bray from Barnstaple, England, was diagnosed with motor neuron disease (MND). MND is a group of neurological disorders that gradually destroy the motor neurons, according to the Cleveland Clinic. These nerve cells are found in the brain and spinal cord, and they control muscle movement for activities like breathing, speaking, swallowing and walking. ALS — also known as Lou Gehrig's disease — is the most common MND. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. 'I've had four different health professionals tell me I've got the worst disease possible,' she told The Mirror in May, using an eye-gazing machine to speak. 'I now feel I am at the stage where my quality of life is very affected, I can no longer use any of my limbs. My talking is severely affected, and I struggle to eat, and it's getting harder to breathe. I am only really comfortable in bed, and social visits are exhausting.' 'I have carers multiple times a day, can't be left alone overnight and can no longer do any basic tasks,' the 42-year-old continued. 'I can't scratch an itch, push up my glasses, or move a bed sheet if I am too hot or cold. I feel like I am losing the essence of me. I am still so loved, but I can't be myself, and I see that grief on everyone's faces." is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! Bray — who actively campaigned for Dignity in Dying — was an advocate for the Assisted Dying Bill, which would allow adults in the UK who are terminally ill to have the choice of medical aid in dying. She said, if it were passed, it would've prevented her loved ones suffering for two years with anticipatory grief. 'Imagine seeing your children crying and upset and not be able to hug them or curl up in bed and wipe their tears away,' she told the outlet, referring to her children, age 15 and 14. 'This is hands down the thing I hate the most about motor neurone disease. It's taken my children's mum from them little by little.' So, Bray decided to end her life using the 'voluntarily stopping eating or drinking' practice, also known as VSED. According to nonprofit Compassion & Choices — which provides resources, training and support for those navigating end-of-life health care — VSED is 'when a mentally capable individual decides to control their own dying by making a conscious decision to refuse foods and fluids of any kind.' 'VSED is not an easy death, but with the current law in England, this is the only way I can have control over my death,' Bray explained. 'I want to protect my children from seeing me choke and struggle to breathe. I don't want to die, but I am going to and have come to terms with my impending death, and I know I want to die surrounded by loved ones, music and laughter, not in an emergency way after further decline.' 'My last bit of parenting I can do is to limit the suffering and trauma they have to witness,' she added. 'I made a promise to myself that I wanted to wait to see my daughter finish high school and my son grow up a little so I can picture the man he will become.' ! In her final months, she told the outlet that she's urging members of parliament to help others 'die with peace.' On Monday, July 14, Bray — from her @stupid_mnd account — posted on Instagram, announcing her own death alongside a final photo of herself lying in a hospice bed overlooking the trees. 'If you are reading this then I've finished my final spin round the sun,' she wrote. 'I've lived a very good life, surrounded by love, music and laughter and I want this to continue in my memory. Rather than shed a tear (or whilst you do) please plant a tree or call a friend, do a random act of kindness or take time to watch a sunset. For moments of doubt please ask 'what would Emma do?' and run with that probably inappropriate answer.' 'Hug everyone a little tighter and love openly,' she ended. 'Please surround those who were closest to me with love, time and patience. And to quote Frank Turner - Remember you get to dance another day but now you have to dance for one more of us. Love you , bye.' Read the original article on People

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store